NEW YORK, Jan. 6, 2022 /PRNewswire/ — Pomerantz LLP announces that a class action lawsuit has been filed against Revance Therapeutics, Inc. (“Revance” or the “Company”) (RVNC) – Get Revance Therapeutics, Inc. Report and certain of Read more…
NEW YORK, Jan. 6, 2022 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of IronNet, Inc. (“IronNet” or the “Company”) (IRNT) . Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, Read more…
NEW YORK, Jan. 6, 2022 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of Talis Biomedical Corporation (“Talis” or the “Company”) (NASDAQ: TLIS). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, Read more…
NEW YORK, Jan. 6, 2022 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of TPI Composites, Inc. (“TPI” or the “Company”) (TPIC) – Get TPI Composites, Inc. Report. Such investors are advised to contact Robert Read more…
NEW YORK, Jan. 6, 2022 /PRNewswire/ — Pomerantz LLP announces that a class action lawsuit has been filed against Owlet, Inc. (“Owlet” or the “Company”) f/k/a Sandbridge Acquisition Corporation (“Sandbridge”) (NYSE: OWLT; OWLT WS; SBG) and certain Read more…
Photo by Dan Seifert / The Verge The US International Trade Commission has ruled that Google is in violation of five Sonos patents relating to smart speakers (via The New York Times). The decision affirms Read more…
NEW YORK, Jan. 6, 2022 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of Redwire Corporation f/k/a Genesis Park Acquisition Corp. (“Redwire” or the “Company”) (NYSE: RDW). Such investors are advised to contact Robert S. Willoughby Read more…
NEW YORK, Jan. 6, 2022 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of Sleep Number Corporation f/k/a Select Comfort Corporation (“Sleep Number” or the “Company”) (NASDAQ: SNBR). Such investors are advised to contact Robert S. Willoughby Read more…
SAN CARLOS, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) — Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that Fred Vogt, PhD, Esq., Interim Chief Executive Officer, Read more…
NEW YORK, Jan. 6, 2022 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of Zhangmen Education Inc. (“Zhangmen” or the “Company”) (NYSE: ZME). Such investors are advised to contact Robert S. Willoughby at [email protected] or Read more…